Developing Strategies to Drive Value in Mental Health Care, Part 3

February 14, 2022

Webinar

Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.

In the latest Matters in Managed Care webinar, experts discussed the current state of mental health care, including the growing consensus on the need for change, strategies to provide high value care, and opportunities for collaboration among payers and other healthcare stakeholders.

The speakers highlighted common challenges for employers and payers regarding coverage for mental health care; discussed common definitions of value for payers, employers, and people with lived experience; shared strategies to incentivize high-value interventions for mental health care; and identified opportunities for future collaboration.

The speakers were:

Schroeder Stribling, MSW, president and CEO, Mental Health America
Michael Thompson, president and CEO, National Alliance of Healthcare Purchaser Coalitions
Jennifer Bright, MPA, executive director, Innovation and Value Initiative
Kevin Ronneberg, MD, vice president and associate medical director, HealthPartners

In segment 3, they discussed existing incentives in mental health care and whether or not they make sense.

Watch Segment 1.

Watch Segment 2.

Watch Segment 4.

Related Content

Adults and adolescents with sickle cell disease experienced early, sustained, and clinically meaningful improvements in HRQOL measures following exa-cel infusion. | Image credit: Ezume Images - stock.adobe.com

Gene Therapy Meaningfully Improves Quality of Life in Severe Sickle Cell Disease

August 29th 2025

Article

Patients with severe sickle cell disease experienced significant quality of life improvements after receiving exagamglogene autotemcel gene therapy.

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

July 15th 2025

Podcast

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Listen

PACE participants | Image: National PACE Association

PACE Program Expansion Requires For-Profit Investment, Reduced Regulatory Burden, and Greater Patient Eligibility

August 19th 2025

Article

Given the track record of good outcomes and savings, policy leaders must do more to promote growth of for-profit PACE programs, the author asserts.

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

June 10th 2025

Podcast

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

Listen

While the findings suggest that switching to onasemnogene abeparvovec after non–gene therapy treatments could be beneficial to patients with spinal muscular atrophy, it is not clear which patients may benefit the most from switching therapies. | Image credit: Rochu_2008 - stock.adobe.com

Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA

August 15th 2025

Article

Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.